“Investigation of Outcomes in Patients with Surgically Resected Melanoma Brain Metastases and Identification of Predictors of Outcome – A Retrospective, Single-Center Cohort Study at the University Hospital Düsseldorf (MeBRO-DUS – Melanoma Brain Resection Outcomes – Düsseldorf Study).”

“Investigation of Outcomes in Patients with Surgically Resected Melanoma Brain Metastases and Identification of Predictors of Outcome – A Retrospective, Single-Center Cohort Study at the University Hospital Düsseldorf (MeBRO-DUS – Melanoma Brain Resection Outcomes – Düsseldorf Study).” - MeBRO-DUS

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00040182

Enrollment

120

Registered

2026-04-30

Start date

2026-03-09

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

melanoma brain metastases

Interventions

Group 1: A retrospective analysis of all patients who underwent neurosurgical resection of brain metastases from melanoma at the University Hospital of Düsseldorf between January 1, 2010, and February

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients were identified using a list of cases involving brain metastases from malignant melanoma provided by the Department of Neuropathology at the University Hospital Düsseldorf. Patients were enrolled in the study if they met the following criteria: the presence of brain metastases from malignant melanoma and the performance of surgical resection of the brain metastases at the University Hospital Düsseldorf.

Exclusion criteria

Exclusion criteria: The patients had previously undergone resection of melanoma brain metastases at another hospital; the patients did not have melanoma brain metastases, but rather, for example, spinal metastases, or they had only undergone a stereotactic biopsy and no surgical resection.

Design outcomes

Primary

Measure	Time frame
- Overall survival (OS) = time from the date of surgical resection of melanoma brain metastases until the patient’s death (in months) - Intracranial progression-free survival (icPFS) = Time from surgical resection of brain metastases to radiological progression of existing brain metastases, the occurrence of new intracranial metastases or LMD, or death from any cause (in months) - Extracranial progression-free survival (ecPFS) = Time from surgical resection of brain metastases until tumor regrowth, the occurrence of new extracranial metastases, or death from any cause (in months)	—

Measure

Time frame

- Overall survival (OS) = time from the date of surgical resection of melanoma brain metastases until the patient’s death (in months) - Intracranial progression-free survival (icPFS) = Time from surgical resection of brain metastases to radiological progression of existing brain metastases, the occurrence of new intracranial metastases or LMD, or death from any cause (in months) - Extracranial progression-free survival (ecPFS) = Time from surgical resection of brain metastases until tumor regrowth, the occurrence of new extracranial metastases, or death from any cause (in months)

—

Secondary

Measure	Time frame
- Occurrence of leptomeningeal metastases (LMD) up to the time of the last follow-up - Association between clinical symptoms (Neurological Symptom Score: NSS 0 = asymptomatic, 1 = mild, 2 = moderate, 3 = severe) and outcome - Effect of frailty level (measured using the mFI5 score) on patient outcomes	—

Countries

Germany

Contacts

Public ContactDavid Wasilewski

Klinik für Neurochirurgie am Universitätsklinikum Düsseldorf

David.Wasilewski@med.uni-duesseldorf.deDavid.Wasilewski@med.u

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Jun 11, 2026